• Immunotherapy Showing High Response Rate in Rare Lymphoma Called ENKTL, Trial Reports
  • MorphoSys Requests FDA Approval of Tafasitamab for Relapsed or Refractory DLBCL
  • Here’s to a New Year and a New Chapter
  • Venclexta-rituximab Combo Shows Long-term Survival Benefits for Relapsed CLL Patients
  • Bristol-Myers Seeks FDA Approval of CAR T-cell Therapy Liso-Cel for Aggressive Large B-cell Lymphomas
  • FDA Grants Orphan Drug Status to CLR 131 for Lymphoplasmacytic Lymphoma Treatment
  • Revlimid-Rituximab Combo Approved in Europe for Previously Treated Follicular Lymphoma
  • Meeting with FDA Supports Tazemetostat for Some Follicular Lymphoma
  • Health Canada Approves Adcetris-Chemo Combo for Initial Peripheral T-cell Lymphoma Treatment
  • Lighter Days Are Around the Corner
  • CHMP Favors Revlimid-Rituximab Combo for Advanced Follicular Lymphoma Patients in EU